We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
DELISTED
Sage Therapeutics
SAGE
$6.58M 1.01%
721,599
-20,896
-3% -$154K
RAPT
27
DELISTED
RAPT Therapeutics
RAPT
$6.27M 0.96%
783,217
+36,871
+5% +$281K
JANX icon
28
CALL
Janux Therapeutics
JANX
$925M
$6.12M 0.94%
264,900
– –
AAM
29
DELISTED
AA Mission Acquisition Corp
AAM
$6.03M 0.92%
578,359
– –
IONS icon
30
Ionis Pharmaceuticals
IONS
$8.6B
$5.87M 0.9%
+148,461
New +$4.86M
TEVA icon
31
Teva Pharmaceuticals
TEVA
$40.8B
$5.8M 0.89%
345,878
-177,889
-34% -$2.87M
OACCU
32
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$5.48M 0.84%
516,482
– –
VERV
33
DELISTED
Verve Therapeutics
VERV
$5.27M 0.81%
+469,018
New +$2.67M
RVMD icon
34
Revolution Medicines
RVMD
$39.9B
$4.93M 0.76%
134,136
-43,000
-24% -$1.65M
BBOT
35
BridgeBio Oncology
BBOT
$648M
$4.7M 0.72%
442,615
-27,114
-6% -$293K
SHY icon
36
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
$4.42M 0.68%
53,337
-50,000
-48% -$4.13M
RZLT icon
37
Rezolute
RZLT
$454M
$4.41M 0.68%
989,297
-126,750
-11% -$471K
MLYS icon
38
Mineralys Therapeutics
MLYS
$2.25B
$4.09M 0.63%
302,125
+38,700
+15% +$561K
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
$3.9M 0.6%
296,766
+80,600
+37% +$1.02M
MNPR icon
40
Monopar Therapeutics
MNPR
$726M
$3.61M 0.55%
100,974
+200
+0.2% +$7.26K
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.57B
$3.6M 0.55%
210,313
+87,392
+71% +$3.73M
ARDX icon
42
Ardelyx
ARDX
$1.22B
$3.59M 0.55%
915,130
+424,387
+86% +$1.75M
THRD
43
DELISTED
Third Harmonic Bio
THRD
$3.38M 0.52%
622,873
+522,873
+523% +$2.61M
PCVX icon
44
Vaxcyte
PCVX
$7.81B
$3.19M 0.49%
98,032
+85,232
+666% +$2.79M
RYTM icon
45
Rhythm Pharmaceuticals
RYTM
$6.81B
$2.87M 0.44%
45,390
+8,500
+23% +$520K
VRNA
46
DELISTED
Verona Pharma
VRNA
$2.69M 0.41%
28,450
+8,450
+42% +$626K
ALEC icon
47
Alector
ALEC
$168M
$2.41M 0.37%
1,723,526
+1,343,196
+353% +$1.68M
VRDN icon
48
Viridian Therapeutics
VRDN
$2.09B
$2.38M 0.37%
170,598
+91,598
+116% +$1.24M
ASPC
49
A SPAC III Acquisition Corp
ASPC
$24.8M
$2.2M 0.34%
215,000
– –
CRMD icon
50
CorMedix
CRMD
$591M
$2.16M 0.33%
+175,000
New +$1.93M
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.